Summary
Introduction
Insulin-induced hypoglycaemia has been found to stimulate the release of renin (Otsuka, Assaykeen, Goldfien & Ganong, 1970; Assaykeen, Clayton, Goldfien & Ganong, 1970; Hedeland, Dymling & Hokfelt, 1972; Lowder, Frazer & Liddle, 1975) . This renin release is apparently mediated by a Padrenergic mechanism since (1) it is accompanied by an increase in plasma catecholamine concentrations, (2) it is blocked by adrenalectomy, and (3) it is blocked by the Padrenoreceptor antagonist propranolol and the cradrenoreceptor agonist clonidine. We have found that renal prostaglandins mediate adrenergically stimulated renin release based on the observations that the prostaglandinsynthesis inhibitors, indomethacin and meclofenamate, block this form of renin release (Campbell, Graham & Jackson, 1979a) . To examine this mechanism further, we have examined the effect of prostaglandin-synthesis inhibition on the adrenergically mediated renin release stimulated by insulin in the conscious rat.
Methods
Male Sprague-Dawley rats (250-300 g/body weight) (Simonsen Laboratories, Gilroy, California, U.S.A.) were used in these studies. Rats were maintained on Wayne rat chow and tap water to drink.
Indwelling arterial catheters were placed in the descending abdominal aorta by the method of Weeks (1970). After allowing 3-4 days for the rats to recover from the surgery, the rats were placed in cages in a quiet room and their arterial catheters connected to a Narco RP-1500 pressure transducer and heart-rate and blood-pressure recorder on a Grass model 7 Polygraph (Campbell et al., 1979a; Campbell, Jackson & Graham, 1979b) . After 60 min for stabilization of blood pressure and heart rate, the rats were divided into two groups. One group was injected subcutaneously at time 0 with olive oil (1 ml/kg), and the other group was injected with indomethacin (14 pmol/kg) (Sigma) suspended in olive oil. At 90 min, a blood sample (0.5 ml) was removed from the arterial catheter into an EDTA-containing tube on ice. The blood sample was centrifuged at 4OC until assayed. Both groups of rats were then injected subcutaneously with regular insulin (Lmy) (10 units/kg). At 120 min, a second blood sample (0.5 ml) was taken and treated as previously described. In preliminary studies we have found that the removal of two blood samples (0.5 ml each) over this time does not alter blood pressure, heart rate, plasma renin activity or plasma catecholamine concentrations in conscious rats. Another group of rats were placed in metabolism cages for collection of urine. Urine was collected from 09.00 to 17.00 hours in rats treated with olive oil, indomethacin (14 pmol/kg subcutaneously), insulin (10 units/kg subcutaneously) or indomethacin plus insulin. The urine was then filtered and stored frozen at -2OOC until assayed.
Plasma renin activity was measured by the antibody-trapping method of Poulsen & Jorgensen (1974) , plasma catecholamines by the radio-enzymatic method of Peuler & Johnson (1977) , and urinary prostaglandins by a modification (Campbell et al., 1979% b) of the method of Dray, Charbonnel & Maclouf (1975) . Plasma potassium was measured by flame photometry (Beckman Instruments) and glucose by a Beckman glucose analyser.
Statistical analyses to determine whether the four treatments differed from each other were performed with an analysis of variance. Then Student's t-test was used to determine the statistical significance between the treatments and values are reported in the text and Table 1 .
Results
Insulin increased plasma renin activity from 2.8 & 0.5 to 9.0 f 1.1 pmol h-l ml-I (P < 0.001) as well as increasing plasma noradrenaline and adrenaline (Table 1 ). The increase in plasma adrenaline was greater than the increase in noradrenaline and was more variable. Plasma potassium and glucose were decreased by 16 and 54% respectively. The urinary excretions of prostaglandin E, and F,, were increased significantly by insulin. Blood pressure and heart rate were unaltered.
Indomethacin alone decreased the urinary excretion of prostaglandin E, and F, by 67 and 54% respectively ( Table 1) . The other parameters measured were unchanged.
In contrast, indomethacin inhibited the insulininduced increase in plasma renin activity by 68% (P < 0.01) and completely blocked the insulininduced increases in urinary prostaglandin E, and F,=. Indomethacin failed to reduce the elevated plasma noradrenaline concentrations and tended to further elevate the plasma adrenaline concentrations. However, this latter effect was variable and failed to attain statistical significance. Indomethacin also failed to elevate the reduced plasma potassium and glucose concentrations produced by insulin. Although blood pressure was unchanged, heart rate was found to decrease slightly (12%, P < 0.01).
Dlscussion
Studies have indicated that renal prostaglandins function as important mediators of renin release from the kidney. This conclusion has been based on direct evidence obtained from the administration of the prostaglandin precursor, arachidonic acid, or the various prostaglandins themselves. In these studies, arachidonic acid increased the release of renin both in uiuo and in uitro, an effect blocked by the prostaglandin-synthesis inhibitor indomethacin (Larsson, Weber & Anggard, 1974; Weber, Larsson, Anggard, Hamberg, Corey, Nicolaou & Samuelsson, 1976; Whorton, Misono, Howfield, Frolich, Inagami & Oates, 1977) . Thus arachidonic acid must be converted into one of its prostaglandin metabolites to exert this action. Similarly, prostaglandin E,, prostaglandin D, and prostaglandin I, stimulated renin release fn ufuo (Bolger, Eisner, Ramwell & Slotkoff, 1978; Gerber, Branch, Nies, Gerkens, Shand, Hollilield & Oates, 1978) . However, only the prostaglandin endoperoxides and prostaglandin I, stimulated renin release in uitro (Weber et al., 1976; Whorton el al., 1977) . Since the prostaglandin endoperoxides are converted into prostaglandin I, in the renal cortex (Whorton, Smigel, Oates & Frolich, 1978) , prostaglandin I, appears to be the arachidonic acid metabolite that is involved in the control of renin release.
Additional evidence indicating that endogenous renal prostaglandins participate in the control of renin release has been obtained with the prostaglandin-synthesis inhibitors. In these studies, indomethacin inhibited baroreceptor-mediated renin release (Data, Gerber, Crump, Frolich, Hollifield & Nies, 1978) and sympathetically mediated renin release (Campbell et al., 1979a) but not macula densa-mediated renin release (Norbiato, Bevilaqua, Raggi, Micossi, Moroni & Fasoli, 1978; Campbell et al., 1979b) . These studies suggest that renal prostaglandins function as chemical mediators of baroreceptor-mediated and sympathetically mediated renin release.
In the present study, insulin-induced hypoglycaemia stimulated the release of catecholamines, renal prostaglandins and renin. The prostaglandin-synthesis inhibitor, indomethacin, inhibited this insulin-induced release of renal prostaglandins and renin without reducing the elevated plasma catecholamine concentrations. In fact, the plasma adrenaline concentrations tended to increase more with insulin in indomethacin-pretreated rats than in normal rats. These findings that indomethacin inhibits the release of renin in the presence of elevated concentrations of circulating catecholamines indicate that the prostaglandinsynthesis inhibitor is acting at a site distal to the juxtaglomerular padrenoreceptor. This contention is supported by our previous findings that indomethacin and meclofenamate inhibited adrenergically mediated release of renin that was stimulated by hydrallazine, the beta agonists, isoprenaline and compound H133/22, and dibutyryl cyclic AMP (Campbell et al., 1979a) . These two studies indicate that renal prostaglandins mediate adrenergically stimulated renin release in the rat.
A similar inhibition of insulin-induced renin release has been reported with the padrenoreceptor antagonist propranolol (Assaykeen et al., 1970; Lowder et al., 1975) . As with indomethacin, propranolol blocked insulin-induced renin release without altering the hypoglycaemia, hypokalaemia or catecholamine release caused by insulin (Assaykeen et al., 1970). In contrast, Hedeland et al. (1972) found that clonidine inhibited the increase in catecholamine release and renin release induced by insulin without altering insulin hypoglycaemia. These studies indicate that the adrenergically mediated renin release stimulated by insulin may be inhibited distal to the padrenoreceptor by indomethacin, at the Padrenoreceptor by propranolol, and before the padrenoreceptor at the level of catecholamine release by clonidine.
Alternatively, potassium depletion and hypokalaemia stimulated the release of renin (Abbrecht & Vander, 1970; Galvez, Bay, Roberts & Ferris, 1977) , and this effect was blocked by inhibition of prostaglandin synthesis in the dog (Galvez et al., 1977) . Since insulin reduced the plasma potassium concentrations in this study, the possibility must be considered that hypokalaemia as well as the elevated circulating plasma catecholamines mediated the renin release. However, this possibility appears unlikely since Otsuka et al. (1970) found that maintaining the plasma potassium within the normal range failed to alter insulininduced renin release. This finding, combined with the observations that blocking of padrenoreceptors with propranolol or blocking the increase in circulating catecholamine with adrenalectomy or clonidine inhibit insulin-induced renin release, emphasizes that the sympathetic nervous system rather than hypokalaemia mediates the renin release produced by insulin (Assaykeen el al., 1970; Hedeland et al., 1972; Lowder et al., 1975) .
